Heidi Nauwelaerts
Debiopharm (Switzerland)(CH)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Head and Neck Cancer Studies, Colorectal Cancer Treatments and Studies, Pituitary Gland Disorders and Treatments, Melanoma and MAPK Pathways
Most-Cited Works
- → A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors(2014)325 cited
- → Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial(2023)51 cited
- → Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design(2022)28 cited
- → A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.(2018)23 cited
- → Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advancedNRAS- orBRAF-mutated melanoma(2019)20 cited
- → Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study(2021)17 cited
- → Overall Survival and Biomarker Results from a Phase 2 Study of Mek1/2 Inhibitor Binimetinib (Mek162) in Patients with Advanced Nras-Mutant Melanoma(2014)17 cited
- → Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study(2025)9 cited
- → TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer.(2021)8 cited
- → SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDY(2021)4 cited